INVIVO STUDY OF VINORELBINE ASSOCIATIONS WITH CISPLATIN, 5-FLUOROURACIL OR ACTINOMYCIN-D RELATIVE TO A NON-SMALL-CELL LUNG-CARCINOMA (NSCLCN6-L16)

Authors
ROUSSAKIS C POUCHUS YF GRATAS C RIOU D DIMOU P DABOUIS G MERLE S VERBIST JF
Citation
C. Roussakis et al., INVIVO STUDY OF VINORELBINE ASSOCIATIONS WITH CISPLATIN, 5-FLUOROURACIL OR ACTINOMYCIN-D RELATIVE TO A NON-SMALL-CELL LUNG-CARCINOMA (NSCLCN6-L16), Anti-cancer drug design, 8(2), 1993, pp. 165-171
Citations number
10
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Anti-cancer drug design → ACNP
ISSN journal
02669536
Volume
8
Issue
2
Year of publication
1993
Pages
165 - 171
Database
ISI
SICI code
0266-9536(1993)8:2<165:ISOVAW>2.0.ZU;2-2
Abstract
Vinorelbine (Navelbine(R)) is a new antitumor agent chemically related to the Vinca alkaloid group, but differentiated by its in vivo activi ty relative to non-small-cell lung carcinoma (NSCLC). Studies in the N SCLC-bearing nude mouse of vinorelbine associations with drugs current ly used clinically in phase III (cisplatin, 5-fluorouracil and actinom ycin D) showed that such associations are ineffective or even of negat ive value and that it would be preferable to use vinorelbine alone in a single dose at the maximum tolerated concentration.